18F-Fluorodeoxyglucose Positron Emission Tomography in Oncology and Neurology
|ClinicalTrials.gov Identifier: NCT01180751|
Recruitment Status : Unknown
Verified July 2013 by University of Manitoba.
Recruitment status was: Enrolling by invitation
First Posted : August 12, 2010
Last Update Posted : August 15, 2013
|Condition or disease||Intervention/treatment||Phase|
|Tumors||Radiation: [18F]-Fluorodeoxyglucose||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||1000 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||18F-Fluorodeoxyglucose Positron Emission Tomography in Oncology and Neurology|
|Study Start Date :||July 2010|
|Primary Completion Date :||June 2013|
|Estimated Study Completion Date :||December 2013|
Scanning Procedure: Non-diagnostic Computed Tomography (CT) scan followed by a Diagnostic Positron Emission Tomography (PET) scan.
With each Positron Emission Tomography/Computed Tomography (PET/CT)scan an intravenous administration of radioactive glucose (FDG)is given. This is a weight dependent dosage.
Other Name: FDG (18F-Fluorodeoxyglucose)
- To confirm the diagnostic effectiveness of 18F-Fluorodeoxyglucose(FDG) as compared to the gold standard of histopathological diagnosis. [ Time Frame: Three years ]The primary outcomes of sensitivity and accuracy of 18F-Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) studies will be obtained by comparing results of the PET scan with the gold standard of histopathological diagnosis when those results are available. Comparison to correlative imaging follow-up, and assessment of efficacy based on feedback from referring physicians will be used in the absence of pathologic data.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01180751
|Great West Life PET/CT Centre|
|Winnipeg, Manitoba, Canada, R3E 3P4|
|Principal Investigator:||Daniel P Levin, BSc,MD,FRCPC||Winnipeg Regional Health Authority|